摘要
目的探讨卵巢癌相关肿瘤抗原新基因在卵巢癌诊断和免疫治疗中的应用价值。方法利用网上生物信息学分析软件对筛选到的55个克隆的核苷酸序列进行分析,并检测其中8个新基因在卵巢癌患者和正常女性血清中的抗体。结果55个克隆的核苷酸序列代表45个卵巢癌抗原基因,其中8个是国内外首次发现的在GeneBank中尚未登记的新基因,是具有免疫原性的功能基因。其中OCY-142新基因是抑癌基因BARD1的可剪切变异体,可被CD4+和CD8+T细胞识别。8个卵巢癌肿瘤抗原新基因中7个在卵巢癌患者血清中的阳性率显著高于正常人,7个卵巢癌肿瘤抗原新基因对卵巢癌患者和正常女性进行联合检测,其敏感性和特异性达到96.9%和95.2%。CAl25异常的卵巢癌41例患者中,OCY-142单独检测的阳性率为95.12%,而CA125正常的卵巢癌57例患者中,OCY-142检测发现21例(36.9%)阳性。结论这些卵巢癌相关肿瘤抗原新基因在卵巢癌患者血清中产生的相应抗体可能成为卵巢癌的新的血清学标志物,可能是卵巢癌免疫治疗理想的新靶点。
Objective ： To evaluate the roles of novel antigen genes in diagnosis and immunothreapy of ovarian cancer. Methods ： The genes selected by SEREX and SSH in our previously research works were identified after analysis by bioinformatics, 8 novel antigen phage clones were screened using allogenic sera from 98 patients with ovarian serous papillary eystadenoma. Results： The sequencing results indicated that 55 positive clones represent 45 tumor antigen genes, g of them are novel genes, and they all have immunogenieity. OCY - 142 is the novel - splicing variant of BARD1 （ BRCA） assoclated ring domain 1 ）, and may be recognized by CD8^＋ T cell after MHC - I binding peptide prediction. The positive ratio of 8 novel antigen phage clones in sera of ovrian cancer patients than that in sera of health donors. Using a combination of novel antigen genes, the sensitivity and specificity for detecting ovarian cancer is 96. 9% and 95.2% , respectively. 36. 9% of ovarian cancers with normal CA125 level can be detected out by OCY - 142. Conclusions ： Those novel antigen genes may be valuable tumor marker in diagnosis of ovarian cancer, and may play important roles in ovarian cancer immunotherapy.
出处
《中国优生与遗传杂志》
2010年第1期12-15,共4页
Chinese Journal of Birth Health & Heredity
